Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: A randomised phase II trial GFPC - IFCT 02-01

Pierre Fournel; Alain Vergnenégre; Gilles Robinet; Hervé Léna; Radj Gervais; Hervé Le Caer; Pierre Jean Souquet; Jean Michel Chavaillon; Marie Cécile Bozonnat; Jean Pierre Daurès; Christos Chouaid; Isabelle Martel-Lafay; P. Fournel; J. N. Talabard; A. Vergnenégre; B. Melloni; C. Decroisette; P. Clavére; G. Robinet; S. Bayle; J. P. Labat; H. Léna; C. Belleguic; M. Benchalal; R. Gervais; A. Rivière; D. Lerouge; P. J. Souquet; L. Gérinière; A. D'Hombres; F. Mornex; H. Le Caer; E. Tessier; H. Ramos; J. M. Chavaillon; C. Chouaid; E. Touboul; S. Bota; L. Thiberville; O. Gallocher; E. Quoix; B. Mennecier; G. M. Jung; L. Falchero; D. Paillotin; S. Schouabe; E. Jonveaux; J. C. Bout; P. Martin; M. Perol; D. Arpin; I. Martel-Lafay; J. Letreut; R. Poirier; A. Benyoub; J. M. Vernejoux; R. Trouette; E. Dansin; H. Berard; J. C. Pietra; G. Zalcman; P. Thomas; A. Zribi; B. Milleron; A. Lavolé; D. Coetmeur; B. Lamezec; C. Bonnamour; V. Grangeon; J. P. Suchaud; J. Créquit; S. Ramdane; P. Barre; M. A. Zawadi; C. Gimenez; F. Barlesi; T. Pignon; M. Grivaux; F. Blanchon; J. Mandet; D. Perdu; A. Cauchois; J. Y. Delhoume; B. Kin; P. Merle; H. Janicot; P. Verrelle; J. B. Auliac; Y. Coscas; A. Ducolone; D. Herman; A. Roquette

doi:10.1016/j.ejca.2015.10.072

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: A randomised phase II trial GFPC - IFCT 02-01

Pierre Fournel, Alain Vergnenégre, Gilles Robinet, Hervé Léna, Radj Gervais, Hervé Le Caer, Pierre Jean Souquet, Jean Michel Chavaillon, Marie Cécile Bozonnat, Jean Pierre Daurès, Christos Chouaid, Isabelle Martel-Lafay, P. Fournel, J. N. Talabard, A. Vergnenégre, B. Melloni, C. Decroisette, P. Clavére, G. Robinet, S. BayleJ. P. Labat, H. Léna, C. Belleguic, M. Benchalal, R. Gervais, A. Rivière, D. Lerouge, P. J. Souquet, L. Gérinière, A. D'Hombres, F. Mornex, H. Le Caer, E. Tessier, H. Ramos, J. M. Chavaillon, C. Chouaid, E. Touboul, S. Bota, L. Thiberville, O. Gallocher, E. Quoix, B. Mennecier, G. M. Jung, L. Falchero, D. Paillotin, S. Schouabe, E. Jonveaux, J. C. Bout, P. Martin, M. Perol, D. Arpin, I. Martel-Lafay, J. Letreut, R. Poirier, A. Benyoub, J. M. Vernejoux, R. Trouette, E. Dansin, H. Berard, J. C. Pietra, G. Zalcman, P. Thomas, A. Zribi, B. Milleron, A. Lavolé, D. Coetmeur, B. Lamezec, C. Bonnamour, V. Grangeon, J. P. Suchaud, J. Créquit, S. Ramdane, P. Barre, M. A. Zawadi, C. Gimenez, F. Barlesi, T. Pignon, M. Grivaux, F. Blanchon, J. Mandet, D. Perdu, A. Cauchois, J. Y. Delhoume, B. Kin, P. Merle, H. Janicot, P. Verrelle, J. B. Auliac, Y. Coscas, A. Ducolone, D. Herman, A. Roquette

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Purpose The objective of this randomised phase II study was to evaluate the impact in terms of response and toxicities of induction or consolidation chemotherapy respectively before or after concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. Patients and methods In the induction arm, patients received induction chemotherapy with cisplatin (80 mg/m²) and paclitaxel (200 mg/m²) on days 1 and 29 followed by a concurrent chemoradiotherapy (66 Gy in 33 fractions, cisplatin 80 mg/m² days 1, 29 and 57, vinorelbine 15 mg/m² days 1, 8, 29, 36, 57 and 64). In consolidation arm, the same concurrent chemoradiotherapy began on day 1 followed by two cycles of cisplatin and paclitaxel. Results One hundred twenty seven patients were randomised. The intent to treat response rates in induction and consolidation arms were 58% and 56% respectively. Median survival was 19.6 months in induction arm and 16.3 months in consolidation arm and 4-year survival rates were 21% and 30% respectively. Haematologic and non-haematologic toxicities were similar in both arms, except grade 3/4 oesophagitis, more frequent in consolidation arm than in induction arm (17% versus 10%). Conclusion Cisplatin-based chemotherapy as induction or consolidation with concurrent chemoradiotherapy can be administrated safely. Response rates were similar in both arms with a trend in favour for consolidation arm for long-term survival.

Original language	English
Pages (from-to)	181-187
Number of pages	7
Journal	European Journal of Cancer
Volume	52
DOIs	https://doi.org/10.1016/j.ejca.2015.10.072
Publication status	Published - 1 Jan 2016

Keywords

Chemotherapy
Lung cancer
Radiotherapy
Therapeutics

Access to Document

10.1016/j.ejca.2015.10.072

Cite this

Fournel, P., Vergnenégre, A., Robinet, G., Léna, H., Gervais, R., Le Caer, H., Souquet, P. J., Chavaillon, J. M., Bozonnat, M. C., Daurès, J. P., Chouaid, C., Martel-Lafay, I., Fournel, P., Talabard, J. N., Vergnenégre, A., Melloni, B., Decroisette, C., Clavére, P., Robinet, G., ... Roquette, A. (2016). Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: A randomised phase II trial GFPC - IFCT 02-01. European Journal of Cancer, 52, 181-187. https://doi.org/10.1016/j.ejca.2015.10.072

@article{f2c8225da5a444bf9cad12e1f3f9c84e,

title = "Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: A randomised phase II trial GFPC - IFCT 02-01",

abstract = "Purpose The objective of this randomised phase II study was to evaluate the impact in terms of response and toxicities of induction or consolidation chemotherapy respectively before or after concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. Patients and methods In the induction arm, patients received induction chemotherapy with cisplatin (80 mg/m2) and paclitaxel (200 mg/m2) on days 1 and 29 followed by a concurrent chemoradiotherapy (66 Gy in 33 fractions, cisplatin 80 mg/m2 days 1, 29 and 57, vinorelbine 15 mg/m2 days 1, 8, 29, 36, 57 and 64). In consolidation arm, the same concurrent chemoradiotherapy began on day 1 followed by two cycles of cisplatin and paclitaxel. Results One hundred twenty seven patients were randomised. The intent to treat response rates in induction and consolidation arms were 58% and 56% respectively. Median survival was 19.6 months in induction arm and 16.3 months in consolidation arm and 4-year survival rates were 21% and 30% respectively. Haematologic and non-haematologic toxicities were similar in both arms, except grade 3/4 oesophagitis, more frequent in consolidation arm than in induction arm (17% versus 10%). Conclusion Cisplatin-based chemotherapy as induction or consolidation with concurrent chemoradiotherapy can be administrated safely. Response rates were similar in both arms with a trend in favour for consolidation arm for long-term survival.",

keywords = "Chemotherapy, Lung cancer, Radiotherapy, Therapeutics",

author = "Pierre Fournel and Alain Vergnen{\'e}gre and Gilles Robinet and Herv{\'e} L{\'e}na and Radj Gervais and {Le Caer}, Herv{\'e} and Souquet, {Pierre Jean} and Chavaillon, {Jean Michel} and Bozonnat, {Marie C{\'e}cile} and Daur{\`e}s, {Jean Pierre} and Christos Chouaid and Isabelle Martel-Lafay and P. Fournel and Talabard, {J. N.} and A. Vergnen{\'e}gre and B. Melloni and C. Decroisette and P. Clav{\'e}re and G. Robinet and S. Bayle and Labat, {J. P.} and H. L{\'e}na and C. Belleguic and M. Benchalal and R. Gervais and A. Rivi{\`e}re and D. Lerouge and Souquet, {P. J.} and L. G{\'e}rini{\`e}re and A. D'Hombres and F. Mornex and {Le Caer}, H. and E. Tessier and H. Ramos and Chavaillon, {J. M.} and C. Chouaid and E. Touboul and S. Bota and L. Thiberville and O. Gallocher and E. Quoix and B. Mennecier and Jung, {G. M.} and L. Falchero and D. Paillotin and S. Schouabe and E. Jonveaux and Bout, {J. C.} and P. Martin and M. Perol and D. Arpin and I. Martel-Lafay and J. Letreut and R. Poirier and A. Benyoub and Vernejoux, {J. M.} and R. Trouette and E. Dansin and H. Berard and Pietra, {J. C.} and G. Zalcman and P. Thomas and A. Zribi and B. Milleron and A. Lavol{\'e} and D. Coetmeur and B. Lamezec and C. Bonnamour and V. Grangeon and Suchaud, {J. P.} and J. Cr{\'e}quit and S. Ramdane and P. Barre and Zawadi, {M. A.} and C. Gimenez and F. Barlesi and T. Pignon and M. Grivaux and F. Blanchon and J. Mandet and D. Perdu and A. Cauchois and Delhoume, {J. Y.} and B. Kin and P. Merle and H. Janicot and P. Verrelle and Auliac, {J. B.} and Y. Coscas and A. Ducolone and D. Herman and A. Roquette",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",

year = "2016",

month = jan,

day = "1",

doi = "10.1016/j.ejca.2015.10.072",

language = "English",

volume = "52",

pages = "181--187",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Fournel, P, Vergnenégre, A, Robinet, G, Léna, H, Gervais, R, Le Caer, H, Souquet, PJ, Chavaillon, JM, Bozonnat, MC, Daurès, JP, Chouaid, C, Martel-Lafay, I, Fournel, P, Talabard, JN, Vergnenégre, A, Melloni, B, Decroisette, C, Clavére, P, Robinet, G, Bayle, S, Labat, JP, Léna, H, Belleguic, C, Benchalal, M, Gervais, R, Rivière, A, Lerouge, D, Souquet, PJ, Gérinière, L, D'Hombres, A, Mornex, F, Le Caer, H, Tessier, E, Ramos, H, Chavaillon, JM, Chouaid, C, Touboul, E, Bota, S, Thiberville, L, Gallocher, O, Quoix, E, Mennecier, B, Jung, GM, Falchero, L, Paillotin, D, Schouabe, S, Jonveaux, E, Bout, JC, Martin, P, Perol, M, Arpin, D, Martel-Lafay, I, Letreut, J, Poirier, R, Benyoub, A, Vernejoux, JM, Trouette, R, Dansin, E, Berard, H, Pietra, JC, Zalcman, G, Thomas, P, Zribi, A, Milleron, B, Lavolé, A, Coetmeur, D, Lamezec, B, Bonnamour, C, Grangeon, V, Suchaud, JP, Créquit, J, Ramdane, S, Barre, P, Zawadi, MA, Gimenez, C, Barlesi, F, Pignon, T, Grivaux, M, Blanchon, F, Mandet, J, Perdu, D, Cauchois, A, Delhoume, JY, Kin, B, Merle, P, Janicot, H, Verrelle, P, Auliac, JB, Coscas, Y, Ducolone, A, Herman, D & Roquette, A 2016, 'Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: A randomised phase II trial GFPC - IFCT 02-01', European Journal of Cancer, vol. 52, pp. 181-187. https://doi.org/10.1016/j.ejca.2015.10.072

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: A randomised phase II trial GFPC - IFCT 02-01. / Fournel, Pierre; Vergnenégre, Alain; Robinet, Gilles et al.
In: European Journal of Cancer, Vol. 52, 01.01.2016, p. 181-187.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation

T2 - A randomised phase II trial GFPC - IFCT 02-01

AU - Fournel, Pierre

AU - Vergnenégre, Alain

AU - Robinet, Gilles

AU - Léna, Hervé

AU - Gervais, Radj

AU - Le Caer, Hervé

AU - Souquet, Pierre Jean

AU - Chavaillon, Jean Michel

AU - Bozonnat, Marie Cécile

AU - Daurès, Jean Pierre

AU - Chouaid, Christos

AU - Martel-Lafay, Isabelle

AU - Fournel, P.

AU - Talabard, J. N.

AU - Vergnenégre, A.

AU - Melloni, B.

AU - Decroisette, C.

AU - Clavére, P.

AU - Robinet, G.

AU - Bayle, S.

AU - Labat, J. P.

AU - Léna, H.

AU - Belleguic, C.

AU - Benchalal, M.

AU - Gervais, R.

AU - Rivière, A.

AU - Lerouge, D.

AU - Souquet, P. J.

AU - Gérinière, L.

AU - D'Hombres, A.

AU - Mornex, F.

AU - Le Caer, H.

AU - Tessier, E.

AU - Ramos, H.

AU - Chavaillon, J. M.

AU - Chouaid, C.

AU - Touboul, E.

AU - Bota, S.

AU - Thiberville, L.

AU - Gallocher, O.

AU - Quoix, E.

AU - Mennecier, B.

AU - Jung, G. M.

AU - Falchero, L.

AU - Paillotin, D.

AU - Schouabe, S.

AU - Jonveaux, E.

AU - Bout, J. C.

AU - Martin, P.

AU - Perol, M.

AU - Arpin, D.

AU - Martel-Lafay, I.

AU - Letreut, J.

AU - Poirier, R.

AU - Benyoub, A.

AU - Vernejoux, J. M.

AU - Trouette, R.

AU - Dansin, E.

AU - Berard, H.

AU - Pietra, J. C.

AU - Zalcman, G.

AU - Thomas, P.

AU - Zribi, A.

AU - Milleron, B.

AU - Lavolé, A.

AU - Coetmeur, D.

AU - Lamezec, B.

AU - Bonnamour, C.

AU - Grangeon, V.

AU - Suchaud, J. P.

AU - Créquit, J.

AU - Ramdane, S.

AU - Barre, P.

AU - Zawadi, M. A.

AU - Gimenez, C.

AU - Barlesi, F.

AU - Pignon, T.

AU - Grivaux, M.

AU - Blanchon, F.

AU - Mandet, J.

AU - Perdu, D.

AU - Cauchois, A.

AU - Delhoume, J. Y.

AU - Kin, B.

AU - Merle, P.

AU - Janicot, H.

AU - Verrelle, P.

AU - Auliac, J. B.

AU - Coscas, Y.

AU - Ducolone, A.

AU - Herman, D.

AU - Roquette, A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose The objective of this randomised phase II study was to evaluate the impact in terms of response and toxicities of induction or consolidation chemotherapy respectively before or after concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. Patients and methods In the induction arm, patients received induction chemotherapy with cisplatin (80 mg/m2) and paclitaxel (200 mg/m2) on days 1 and 29 followed by a concurrent chemoradiotherapy (66 Gy in 33 fractions, cisplatin 80 mg/m2 days 1, 29 and 57, vinorelbine 15 mg/m2 days 1, 8, 29, 36, 57 and 64). In consolidation arm, the same concurrent chemoradiotherapy began on day 1 followed by two cycles of cisplatin and paclitaxel. Results One hundred twenty seven patients were randomised. The intent to treat response rates in induction and consolidation arms were 58% and 56% respectively. Median survival was 19.6 months in induction arm and 16.3 months in consolidation arm and 4-year survival rates were 21% and 30% respectively. Haematologic and non-haematologic toxicities were similar in both arms, except grade 3/4 oesophagitis, more frequent in consolidation arm than in induction arm (17% versus 10%). Conclusion Cisplatin-based chemotherapy as induction or consolidation with concurrent chemoradiotherapy can be administrated safely. Response rates were similar in both arms with a trend in favour for consolidation arm for long-term survival.

AB - Purpose The objective of this randomised phase II study was to evaluate the impact in terms of response and toxicities of induction or consolidation chemotherapy respectively before or after concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. Patients and methods In the induction arm, patients received induction chemotherapy with cisplatin (80 mg/m2) and paclitaxel (200 mg/m2) on days 1 and 29 followed by a concurrent chemoradiotherapy (66 Gy in 33 fractions, cisplatin 80 mg/m2 days 1, 29 and 57, vinorelbine 15 mg/m2 days 1, 8, 29, 36, 57 and 64). In consolidation arm, the same concurrent chemoradiotherapy began on day 1 followed by two cycles of cisplatin and paclitaxel. Results One hundred twenty seven patients were randomised. The intent to treat response rates in induction and consolidation arms were 58% and 56% respectively. Median survival was 19.6 months in induction arm and 16.3 months in consolidation arm and 4-year survival rates were 21% and 30% respectively. Haematologic and non-haematologic toxicities were similar in both arms, except grade 3/4 oesophagitis, more frequent in consolidation arm than in induction arm (17% versus 10%). Conclusion Cisplatin-based chemotherapy as induction or consolidation with concurrent chemoradiotherapy can be administrated safely. Response rates were similar in both arms with a trend in favour for consolidation arm for long-term survival.

KW - Chemotherapy

KW - Lung cancer

KW - Radiotherapy

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84949604621&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.10.072

DO - 10.1016/j.ejca.2015.10.072

M3 - Article

C2 - 26689864

AN - SCOPUS:84949604621

SN - 0959-8049

VL - 52

SP - 181

EP - 187

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: A randomised phase II trial GFPC - IFCT 02-01

Abstract

Keywords

Access to Document

Other files and links

Cite this